Tra­con shares slammed by PhII bust in brain can­cer study; Vis­ter­ra yanks its IPO in back-to-back duds

• Shares of San Diego-based Tra­con $TCON got slammed this morn­ing af­ter in­ves­ti­ga­tors said that the Phase II NCI study of TRC105 in re­cur­rent glioblas­toma failed. The study was de­signed to de­tect if a com­bi­na­tion of TRC105 and Avastin could sub­stan­tial­ly im­prove the pro­gres­sion-free sur­vival rate of pa­tients over what would be ex­pect­ed for Avastin alone. That didn’t work. The stock was down 21% in ear­ly trad­ing Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER